Abstract
Trimetrexate glucuronate was evaluated in 70 nonsmall cell lung cancer patients with incurable disease and/or demonstrated progression following surgery/radiotherapy and no prior cytotoxic chemotherapy. Trimetrexate was initially administered at 8 mg/m2 intravenously (IV) daily for 5 days and repeated every 3 to 4 weeks with dose adjustments depending on patient tolerance. A median of two courses of trimetrexate therapy was administered (range 1 to 12). Fifty-nine (84%) patients were evaluable for response. Eleven patients (19%) achieved a partial response with a median duration of 15.3 weeks. The median time to response was 4.6 weeks. Twenty-three patients (39%) had stable disease with a median time to progression of 15.7 weeks. The median survival for evaluable patients was 26.4 weeks. Trimetrexate was well tolerated with manageable myelosuppression as the dose limiting toxicity. Trimetrexate was shown to have activity in nonsmall cell lung cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
